Literature DB >> 6301461

DNA gyrase (Topoisomerase II) from Pseudomonas aeruginosa.

R V Miller, T R Scurlock.   

Abstract

DNA gyrase (Topoisomerase II) has been purified from Pseudomonas aeruginosa strain PAO. This enzyme is inhibited by novobiocin and nalidixic acid. DNA gyrase from P. aeruginosa is resistant to a much higher level of nalidixic acid than is Escherichia coli DNA gyrase. This increased level of resistance may explain, at least in part, the higher levels of natural resistance exhibited by P. aeruginosa toward nalidixic acid.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6301461     DOI： 10.1016/0006-291x(83)91205-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 2.  Biochemical characteristics and physiological significance of major DNA topoisomerases.

Authors:  J A Sutcliffe; T D Gootz; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

4.  Purification and properties of DNA gyrase from Vibrio cholerae.

Authors:  G Mukhopadhyay; A Ghosh
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

5.  [Mechanism of action of quinolones].

Authors:  J T Smith
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.

Authors:  K Hirai; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa.

Authors:  D M Benbrook; R V Miller
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Antimicrobial activity of DV-7751a, a new fluoroquinolone.

Authors:  M Tanaka; K Hoshino; H Ishida; K Sato; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.